COSCIENS Biopharma Inc.
CSCIF
$2.08
-$0.08-3.92%
OTC PK
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 32.65% | 26.10% | 45.70% | -16.96% | -304.71% |
| Total Depreciation and Amortization | 0.00% | -11.69% | -17.09% | -18.16% | 27.06% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -124.23% | 218.70% | -95.24% | 59.43% | 175.02% |
| Change in Net Operating Assets | 139.22% | -282.74% | 75.99% | 118.28% | -326.90% |
| Cash from Operations | 84.80% | -136.54% | 37.31% | 61.45% | -460.04% |
| Capital Expenditure | -- | 92.03% | -99.03% | -135.88% | 16.56% |
| Sale of Property, Plant, and Equipment | 300.00% | -75.00% | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | 42.86% | -103.27% | -- |
| Cash from Investing | 108.33% | 92.20% | -94.62% | -480.72% | -99.68% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -30.77% | 67.50% | -83.49% | 4.39% | 9.52% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -25.68% | -- |
| Cash from Financing | 20.56% | 46.50% | 0.99% | -7.45% | -49.21% |
| Foreign Exchange rate Adjustments | -129.38% | 195.00% | 168.18% | -212.82% | 216.42% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 81.72% | -67.93% | 26.91% | 53.82% | -132.13% |